tiprankstipranks
Advertisement
Advertisement

XENE Stock Latest News

Xenon Shareholders Approve Directors, Pay and Incentive Plan
Company AnnouncementsXenon Shareholders Approve Directors, Pay and Incentive Plan
9h ago
8K
XENE
Xenon Pharmaceuticals price target raised to $82 from $80 at JPMorgan
PremiumThe Fly
Xenon Pharmaceuticals price target raised to $82 from $80 at JPMorgan
8d ago
XENE
Xenon Pharmaceuticals Signals Strong Momentum In Earnings
PremiumCompany Announcements
Xenon Pharmaceuticals Signals Strong Momentum In Earnings
15d ago
XENE
Xenon Pharmaceuticals price target raised to $80 from $77 at JPMorgan
PremiumThe Fly
Xenon Pharmaceuticals price target raised to $80 from $77 at JPMorgan
23d ago
XENE
Xenon Pharmaceuticals price target raised to $69 from $68 at Wells Fargo
PremiumThe Fly
Xenon Pharmaceuticals price target raised to $69 from $68 at Wells Fargo
25d ago
PRAX
XENE
Xenon Pharmaceuticals Maps Path After Standout XTOL-2
PremiumCompany AnnouncementsXenon Pharmaceuticals Maps Path After Standout XTOL-2
26d ago
XENE
Xenon Pharmaceuticals price target lowered to $78 from $80 at Needham
Premium
The Fly
Xenon Pharmaceuticals price target lowered to $78 from $80 at Needham
26d ago
XENE
Analyst Reaffirms Buy on Xenon, Citing Blockbuster Potential for Lead Epilepsy Candidate and Upside from Pipeline Programs
Premium
Ratings
Analyst Reaffirms Buy on Xenon, Citing Blockbuster Potential for Lead Epilepsy Candidate and Upside from Pipeline Programs
27d ago
XENE
Xenon Highlights Positive Phase 3 Azetukalner Seizure Data
PremiumCompany Announcements
Xenon Highlights Positive Phase 3 Azetukalner Seizure Data
27d ago
8K
XENE
Xenon Pharmaceuticals reports Q1 EPS ($1.17), consensus ($1.20)
PremiumThe Fly
Xenon Pharmaceuticals reports Q1 EPS ($1.17), consensus ($1.20)
27d ago
XENE
XENE Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
XENE Upcoming Earnings Report: What to Expect?
30d ago
XENE
Xenon’s Azetukalner: Rapid, Durable Efficacy and Once‑Daily Convenience Underpin Buy Rating and Preferred Second‑Line Epilepsy Positioning
PremiumRatings
Xenon’s Azetukalner: Rapid, Durable Efficacy and Once‑Daily Convenience Underpin Buy Rating and Preferred Second‑Line Epilepsy Positioning
1M ago
XENE
Xenon Pharmaceuticals presents data from Phase 3 X-TOLE2 study
PremiumThe FlyXenon Pharmaceuticals presents data from Phase 3 X-TOLE2 study
2M ago
XENE
Xenon to Spotlight Neurology Pipeline at Series of 2026 Investor Conferences
Premium
Company Announcements
Xenon to Spotlight Neurology Pipeline at Series of 2026 Investor Conferences
2M ago
XENE
Xenon Expands 2025 Inducement Equity Incentive Plan
Premium
Company Announcements
Xenon Expands 2025 Inducement Equity Incentive Plan
2M ago
8K
XENE
Xenon to Unveil Phase 3 Azetukalner Data and Pipeline Advances at 2026 AAN Meeting
PremiumCompany Announcements
Xenon to Unveil Phase 3 Azetukalner Data and Pipeline Advances at 2026 AAN Meeting
2M ago
XENE
Xenon Pharmaceuticals price target lowered to $63 from $64 at Wedbush
PremiumThe Fly
Xenon Pharmaceuticals price target lowered to $63 from $64 at Wedbush
3M ago
XENE
Xenon Sets Date for 2026 Annual Shareholder Meeting
PremiumCompany Announcements
Xenon Sets Date for 2026 Annual Shareholder Meeting
3M ago
8K
XENE
Xenon’s X-TOLE2 Trial Completion Puts XEN1101 in Focus for Epilepsy Investors
PremiumCompany Announcements
Xenon’s X-TOLE2 Trial Completion Puts XEN1101 in Focus for Epilepsy Investors
3M ago
XENE
Xenon Strengthens Balance Sheet With Major Equity Offering
PremiumCompany AnnouncementsXenon Strengthens Balance Sheet With Major Equity Offering
3M ago
8K
XENE
Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00
Premium
The Fly
Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00
3M ago
XENE
Xenon Raises $650 Million in Upsized U.S. Equity Offering
Premium
Company Announcements
Xenon Raises $650 Million in Upsized U.S. Equity Offering
3M ago
XENE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >